KURA - クラ・オンコロジ― （Kura Oncology Inc.）

Kura Oncology Inc. (NASDAQ:KURA) marked $11.04 per share on Thursday, down from a previous closing price of $11.08. While Kura Oncology Inc. has underperformed by -0.36%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KURA fell by -32.35%, with highs and lows ranging from $19.93 to […]

A share of Kura Oncology Inc. (NASDAQ:KURA) closed at $11.95 per share on Wednesday, up from $11.92 day before. While Kura Oncology Inc. has overperformed by 0.25%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KURA fell by -24.70%, with highs and lows ranging from $19.93 […]

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:

Kura Oncology is axing all but one clinical development program involving an old Janssen candidate. According to an SEC filing on Thursday, Kura has dropped multiple programs for tipifarnib, a farnesyltransferase inhibitor (FTI) that targets a protein called HRAS. The drug was originally discovered by J&J, which handed it off

Kura Oncology, Inc. (NASDAQ:NASDAQ:KURA) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ETCompany ParticipantsPete De Spain - Senior Vice President of Investor Relations and…

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:

Kura Oncology is axing all but one clinical development program involving an old Janssen candidate. According to an SEC filing on Thursday, Kura has dropped multiple programs for tipifarnib, a farnesyltransferase inhibitor (FTI) that targets a protein called HRAS. The drug was originally discovered by J&J, which handed it off

Kura Oncology, Inc. (NASDAQ:NASDAQ:KURA) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ETCompany ParticipantsPete De Spain - Senior Vice President of Investor Relations and…

SAN DIEGO (AP) — SAN DIEGO (AP) — Kura Oncology Inc. (KURA) on Thursday reported a loss of $33.1 million…

Kura Oncology press release (KURA): Q4 GAAP EPS of -$0.49 beats by $0.08.$438 million in cash, equivalents and investments provide runway into fourth quarter of 2025

Kura Oncology Inc. (NASDAQ:KURA) shares, rose in value on Friday, 12/30/22, with the stock price up by 1.31% to the previous day’s close as strong demand from buyers drove the stock to $12.41. Actively observing the price movement in the last trading, the stock closed the session at $12.25, falling within a range of $11.86 … Kura Oncology Inc. (NASDAQ: KURA) Jumps 1.31%: What Could Be On The Way Going Forward? Read More »

Kura Oncology (KURA) slumped and Syndax Pharmaceuticals (SNDX) climbed after Phase 1/2 trial for their respective myeloid leukemia candidates. Read the full story here.

Kura Oncology Inc (NASDAQ: KURA ) announced updated clinical data from the KOMET-001 Phase 1/2 trial of ziftomenib in patients with relapsed/refractory acute myeloid leukemia (AML). Ziftomenib demonstrated optimal clinical benefit at 600 mg with a 30% CR rate (6/20) in patients with NPM1-mutant AML, compared to 17% (1/6) at 200 mg. Notably, four NPM1-mutant patients who achieved a CR at 600 mg … Full story available on Benzinga.com

Kura Oncology Inc. (NASDAQ:KURA)’s traded shares stood at 0.81 million during the last session, with the company’s beta value hitting 0.84. At the close of trading, the stock’s price was $16.00, to imply an increase of 2.76% or $0.43 in intraday trading. The KURA share’s 52-week high remains $19.93, putting it -24.56% down since that … Kura Oncology Inc. (NASDAQ: KURA) Drops -24.56% From Highs, What Happens Next? Read More »

The following slide deck was published by Kura Oncology, Inc.